-
公开(公告)号:US20230127345A1
公开(公告)日:2023-04-27
申请号:US18052814
申请日:2022-11-04
发明人: Sharon Shechter , Eliezer Zomer , Peter G. Traber , Raphael Nir , Joseph M. Johnson , Ryan George
IPC分类号: C07H19/056 , A61P1/16 , A61P9/00 , A61P13/12 , A61P11/00 , A61K31/7056 , A61K45/06
摘要: Aspects of the invention relate to novel synthetic compounds having a binding affinity with galectin proteins.
-
2.
公开(公告)号:US20230076066A1
公开(公告)日:2023-03-09
申请号:US17520787
申请日:2021-11-08
申请人: SAVA HEALTHCARE LTD
IPC分类号: A61K31/53 , A61K9/16 , A61K9/00 , A61K31/7048 , A61K31/4965 , A61K31/7056 , A61K31/675 , A61K31/4045 , A61K31/4706 , A61K38/13 , A61K38/21 , A61K39/395 , A61P31/14
摘要: The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure: for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.
-
公开(公告)号:US20230075885A1
公开(公告)日:2023-03-09
申请号:US17760390
申请日:2021-02-11
IPC分类号: A61K9/16 , A61K47/46 , A61K31/675 , A61K31/352 , A61K41/00 , A61K38/21 , A61K31/215 , A61K31/7056 , A61K31/513 , A61K36/16 , A61K31/07 , A61K31/375 , A61K31/355 , A61K36/258 , A61K36/82 , A61K31/522 , A61K31/122 , A61K36/23
摘要: Compositions in homogenised powder form consisting of hydroxypropyl methylcellulose particles, and at least one chemical signalling agent in particle form, and optionally a biologically active agent, wherein the homogenised powder comprises particles having a mean particle diameter of ≥20 μm to ≤500 μmm uses and kits therefor.
-
公开(公告)号:US20230033327A1
公开(公告)日:2023-02-02
申请号:US17896154
申请日:2022-08-26
发明人: James W. JANETKA , Zhenfu HAN , Scott HULTGREN , Jerry PINKER , CORINNE CUSUMANO
IPC分类号: C07H15/203 , C07H15/26 , A61K31/7034 , A61K31/7042 , A61K31/7056 , A61K31/706 , A61K31/7064 , A61K45/06
摘要: The present invention encompasses compounds and methods for treating and preventing bacterial infections specifically urinary tract infections and those caused by bacteria containing type 1 pili and FimH. The present invention also encompasses compounds and methods for treating inflammatory bowel disease specifically Crohn's Disease.
-
公开(公告)号:US20230022162A1
公开(公告)日:2023-01-26
申请号:US17936379
申请日:2022-09-28
申请人: Esrail Medical Corp.
发明人: Rafi Israel
IPC分类号: A61K31/7056 , A61K31/65 , A61P31/14
摘要: A method of treatment for coronavirus disease 2019 (COVID-19) is disclosed herein. The method comprises administering a therapeutically effective dose of a combination of ribavirin and minocycline. A pharmaceutical composition comprising ribavirin and minocycline is also disclosed herein. The pharmaceutical composition may further include one or more pharmaceutical excipients.
-
公开(公告)号:US20230000892A1
公开(公告)日:2023-01-05
申请号:US17364790
申请日:2021-06-30
申请人: Kenneth Okafor
发明人: Kenneth Okafor
IPC分类号: A61K31/7056 , A61K9/06
摘要: An article of manufacture for providing a solution, lotion, gel, and cream for use as an aftershave to prevent razor bumps is disclosed. A solution, lotion, gel, and cream having a concentration of clindamycin phosphate between 0.5% and 1.0% may be applied immediately after shaving to a user's skin to prevent razor bumps on various parts of the body that are typically shaved. The present invention may be applied as a skin treatment to the face and neck, underarms, legs, and pubic areas.
-
公开(公告)号:US20230000887A1
公开(公告)日:2023-01-05
申请号:US17824362
申请日:2022-05-25
IPC分类号: A61K31/702 , A61K31/7034 , A61K31/7036 , A61K31/7048 , A61K31/7056 , A61K9/00 , A61K9/51 , A61P37/02
摘要: The present invention includes novel compositions and methods for treating comprising a compound with the Formula I: wherein n=0, 1, 2, 3, 4, or 5; X=NH or O or S; Y=phenyl, or a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R=H, C(O)R2, SO2R2; R1=H, C(O)R2, SO2R2; R2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4; R3, R4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl, and Z=NH, or O, or none, and optionally wherein both X and Z are not both S, and wherein the amount of the compound is selected to either inhibit or activate the immune response.
-
公开(公告)号:US11541046B2
公开(公告)日:2023-01-03
申请号:US16627627
申请日:2018-06-29
申请人: Yusheng Xiong , Hong-Ping Guan , Wenjun Huang , Quixgen, Inc.
发明人: Yusheng Xiong , Hong-Ping Guan , Wenjun Huang
IPC分类号: A61K31/4709 , A61P17/10 , A61P1/16 , A61P3/04 , A61K9/00 , A61K31/145 , A61K31/18 , A61K31/192 , A61K31/197 , A61K31/203 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/438 , A61K31/444 , A61K31/575 , A61K31/616 , A61K31/65 , A61K31/7048 , A61K31/7056 , A61K38/26 , A61K47/10 , A61K47/32 , A61K48/00 , C07D491/107 , C07D519/00
摘要: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.
-
公开(公告)号:US20220401554A1
公开(公告)日:2022-12-22
申请号:US17774632
申请日:2020-11-06
申请人: CORNELL UNIVERSITY
IPC分类号: A61K39/29 , A61K31/265 , A61P31/14 , A61P31/22 , A61P31/16 , A61K39/245 , A61K39/275 , A61K39/12 , A61K39/215 , A61K39/145 , A61K39/155 , A61K39/205 , A61K39/21 , A61K31/43 , A61K31/427 , A61K38/14 , A61K31/4164 , A61K31/65 , A61K31/407 , A61K31/575 , A61K31/546 , A61K31/496 , A61K31/7048 , A61K31/7072 , A61K31/522 , A61K31/7076 , A61K31/7056 , A61K31/662 , A61K31/13 , A61K31/196 , A61K31/4709 , A61K38/21 , A61K31/4965 , A61K31/351
摘要: The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with an isolated enveloped virus, having a membrane, to inactivate the membrane of the isolated enveloped virus. The subject is then treated with the enveloped virus having an inactivated membrane to vaccinate the subject against the enveloped virus. Further disclosed is an ex vivo vaccine composition including the compound of Formula (I) and an enveloped virus.
-
10.
公开(公告)号:US11529257B2
公开(公告)日:2022-12-20
申请号:US17092855
申请日:2020-11-09
发明人: Shengxi Chen
IPC分类号: A61F5/41 , A61F6/04 , A61K31/7056 , A61K33/00 , A61K9/00 , B32B27/04 , C08K3/20 , B32B27/40 , A61K9/70
摘要: A condom apparatus including at least one of a condom containing a compound of Formula 1 wherein the condom is configured to deliver one or more active ingredients selected from the group consisting of arginine, a vasodilator, nitrates, an ergot alkaloid, a long acting alpha-adrenoceptor blocker, a short acting alpha-adrenoceptor blocker, an anti-hypertensive, a prostaglandin, and a phosphodiesterase inhibitor is disclosed.
-
-
-
-
-
-
-
-
-